The RTS,S malaria vaccine, recommended for use in children by the World Health Organization in October 2021, is a historic breakthrough in the fight against this disease. The vaccine will be in high demand in malaria-endemic Sub-Saharan African countries. However, in the short term, supply will be limited.
Given these initial supply challenges, as well as the vaccine’s unique characteristics, country governments will need to consider how to prepare for RTS,S vaccine introduction. Countries and partners should apply the experience and lessons learned from implementing and scaling up new vaccine program in recent years to optimize the rollout and uptake of this vaccine.
We strive to build lasting relationships to produce better health outcomes for all.
